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ABSTRACT
Cardiovascular disease (CVD) is the leading cause of death in the United States, and is the 
major source of morbidity and mortality associated with diabetes mellitus. Because the 
incidence of diabetes continues to increase, reducing the risk of CVD in diabetes will 
continue to be a major focus of cardiovascular research. An early manifestation of diabetes-
induced CVD is dysfunction of the vascular endothelium, as indicated by depressed 
production of NO. Our findings now demonstrate depressed activity of endothelial nitric 
oxide synthase (eNOS) in diabetes, and suggest that treating human coronary artery 
endothelial cells with allicin, the major bioactive organosulfur component in garlic extract, 
can restore NO production in these cells. Coronary artery endothelial cells (Lonza) were 
obtained from control (HCAEC) or diabetic (DHCAEC) donors, and NO production was 
measured by fluorescence microscopy via 4,5-diaminofluorescein diacetate. On average, 
NO production was depressed by 12.9% in DHCAEC compared to controls. Treating these 
cells for 20 minutes with 4μM allicin restored NO production by 32.9%. Further, immunoblot 
studies revealed that diabetes decreased expression of eNOS protein by 20.3%; however, 
allicin was able to reverse this effect of diabetes. On average, eNOS expression was 
increased by 26% by overnight exposure to 5μM allicin. Taken together, these data indicate 
that allicin improves endothelium-dependent NO production in diabetes by enhancing the 
expression and/or activity of eNOS in human coronary artery endothelial cells. These 
studies further suggest that this improved endothelial function likely contributes to the 
established health benefits of garlic consumption (e.g., lowering blood pressure), and also 
suggests a natural means of reducing the devastating consequences of diabetes on CVD. 
Future experiments are needed to identify the mechanism of allicin action on eNOS and in 
vascular endothelial cells. 
CONCLUSION
SUMMARY
Our findings demonstrate that allicin:
1.)  increased NO production in DHCAEC-I cells
2.)  increased eNOS expression in DHCAEC-I cells
3.)  has no effect on eNOS expression on HCAEC and DHCAEC-II cells
4.)  modified the eNOS immunocomplex in DHCAEC-I cells
Our data provide supporting evidence for the potential use of allicin as a preventative measure against CVD. We
propose that allicin may aid in treatment of endothelial dysfunction associated with type-I diabetes or other
conditions of high oxidative stress. Future research is needed to analyze the role of specific proteins involved in the
eNOS immunocomplex induced by allicin.
RESULTS
METHOD
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Diabetes mellitus is a consistent rising public health burden in the 21st century, and remains 
a major risk factor for the development of CVD. Currently, diabetes affects over 125 million 
people in the western world, and estimates of its prevalence are expected to surpass 300 
million by 2025 due to a combination of poor diet and lifestyle. Natural garlic (Allium 
sativum) supplementation has been utilized as a remedy for thousands of years in treating 
various chronic diseases. Allicin (2-propene-1-sulfonothioic acid S-2 propenyl ester, diallyl 
thiosulfinate) is the primary active component in garlic, and current literature supports its 
therapeutic effects on lowering blood pressure, decreasing blood glucose levels, reducing 
atherosclerotic plaque formation, and modulating inflammation. This organosulfur 
compound rapidly crosses the cellular membrane and reacts with sulfhydryl groups on 
cellular proteins or with glutathione. It has been demonstrated that allicin increases 
intracellular levels of glutathione and phase II detoxifying enzymes that include glutamate-
cysteine ligase and heme oxygenase-I in vascular endothelial cells. We tested the 
hypothesis that allicin could reverse diabetes-induced inhibition of NO production in human 
coronary artery endothelial cells, possibly by decreasing oxidative stress to lower CVD risk.
Cell Culture: Human coronary artery endothelial cells (HCAEC) from healthy, Type-I, and 
Type II diabetic cell lines(DHCAEC-I; DHCAEC-II) were grown in EBM-2 basal media 
supplemented with EGM-2 MV (Lonza). Passage 4 cells were thawed and used for 
treatment. Cells were changed to phenol-free media 24 hours prior to imaging.
Allicin Treatment: Cells were incubated in 10μM 4,5-Diaminofluorescein diacetate (DAF-
2DA) for 15 minutes at 37°C. Cells were then washed with KREBS solution and incubated 
for 20 minutes at 37°C. Afterwards, cells were incubated with L-NAME and images were 
obtained with EVOS microscope at 10X, 20X, 40X and analyzed using ImageJ software. 
Immunoblotting: Cell lysates (20μg of protein) were analyzed by 8% Tris Glycine SDS 
polyacrylamide gel electrophoresis and transferred to PVDF membrane. The membranes 
were blocked with 5% milk + TBST 0.1% for 1 hour and then probed overnight with a anti-
eNOS antibody (1:10000). Membranes were then incubated with species-specific HRP-
conjugated secondary antibody (1:5000) followed by detection with ECL substrate. 
Quantitation of proteins was determined by densitometry analysis of scanned films using 
ImageJ software.
Mass Spectrometry: Proteins were extracted from cell lines and equal amounts were 
immunoprecipitated with anti-eNOS antibody or control goat IgG. The immune complexes 
were immobilized on the protein A/G ultralink resin. Trypsin digestion and MS analysis were 
performed at the proteomics and metabolomics core facility at the Georgia Cancer Center. 
Scaffold (version Scaffold_4.8.9, Proteome Software, Inc.) was used to validate LC-MS and 
LC-MS/MS-based peptides and protein identification. Peptide identifications were accepted if 
they could be established at >95.0% probability as specified by the Peptide Prophet 
algorithm. 
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Figure 2. L-NAME, an inhibitor of eNOS, attenuated NO production and sodium nitroprusside (SNP) increased NO production in 
HCAEC. Baseline DAF fluorescence was 7.062 + 0.3603 NFU, n=119 cells. L-NAME decreased intensity by 98.3% from baseline, 
(mean 0.1206 + 0.111 NFU, n=41 cells.)_Subsequent treatment with SNP, an exogenous NO donor, significantly increased DAF 
intensity to 16.43 + 2.543 NFU, n=41 cells. This is a 13,524% increase from L-NAME and a 132.7% increase from baseline. Data 
analyzed using Student’s t test. 
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Figure 1. Effect of allicin on NO production and inhibition by L-NAME in DHCAEC-I cells. A. Representative images of NO 
production by DHCAEC-I cells untreated (left panel) allicin-treated (middle panel), and treated with allicin and L-NAME (right 
panel). B. Baseline DAF fluorescence was 8433 + 6276, n=36 cells. Allicin increased mean fluorescence intensity by 292.39% from 
baseline (33090 + 7705 n=18 cells). L-NAME, an inhibitor of eNOS activity, attenuated mean flourescence intensity to 5057+ 5043, 
n=47 cells. This is a 554.34% decrease from allicin treatment. Data are expressed as mean + SEM. Student’s t test was performed. 
Figure 3. Allicin increased eNOS expression. A. Representative immunoblot analysis for eNOS in HCAEC, DHCAEC-I, and DHCAEC-II 
cell lines. β-actin was used as loading control. B. Quantification of eNOS expression in non-treated and allicin treated cell lines of 
HCAEC (n=3), DHCAEC-I (n=3), and DHCAEC (n=3). The data are expressed as mean + SEM. Data analyzed using Student’s t test.
Figure 4. Analysis of eNOS immunocomplex induced by allicin treatment in DHCAEC-I cells by mass spectrometry (MS). To identify proteins, immunocomplexes were 
isolated from allicin-treated and non-treated DHCAEC-I cells using an anti-eNOS antibody and control IgG. LTQ Orbitrap MS was then used to analyze tryptic peptides 
generated following an immunoprecipitation. A. Highest ranking of proteins associated with eNOS complex induced by allicin. 156 indicated as DHCAEC-I cells. B. 
Quantitative scatterplot demonstrated proteins involved in the eNOS immunocomplex of non-treated versus allicin treated DHCAEC-I cells. C. Venn diagram 
representing the amount of proteins associated with the eNOS immunocomplex in each experimental group. 883 proteins are represented in the allicin specific 
immunocomplex of DHCAEC-I cells. D. Representative protein (glutathione synthetase, accession A0A2R8Y6Y6_HUMAN) specific for allicin induced eNOS 
immunocomplex. 
H
C
AE
C
D
H
C
AE
C
-I
D
H
C
AE
C
-II
β-actin
eNOS
A
Allicin increases eNOS expression in DHCAEC-I
Allicin - + + +- -
R
el
at
iv
e 
B
an
d 
In
te
ns
ity
(e
N
O
S
/β
-a
ct
in
)
Allicin - + - + - +
HCAEC DHCAEC-I DHCAEC-II
B
p < 0.05
H2S
Allicin
Alliin
Polysulfides
Glutathione
Pentose Phosphate Pathway
NADPH
Proposed Vasodilatory Mechanism of Allicin
Allinase
